JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
81% less call options, than puts
Call options by funds: $596K | Put options by funds: $3.22M
Holders
124
Holding in Top 10
2
Calls
$596K
Puts
$3.22M
Top Buyers
| 1 | +$33.5M | |
| 2 | +$24.1M | |
| 3 | +$18.7M | |
| 4 |
CCM
CAAS Capital Management
New York
|
+$10.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.82M |
Top Sellers
| 1 | -$27.7M | |
| 2 | -$6.59M | |
| 3 | -$4.25M | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.46M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.21M |